New pill shows promise for rare gut tumors
NCT ID NCT05077384
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a daily pill called surufatinib in 36 Japanese patients with neuroendocrine tumors that had stopped responding to other treatments. The goal was to see if the drug is safe and whether it can shrink tumors. The trial combined an early safety phase with a later phase measuring tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib (a drug taken by mouth once daily)
What this could lead to
If successful, surufatinib could offer a new treatment option for patients with neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase study with only 36 participants, so results may not apply broadly. Side effects are possible, and the drug may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Centre
Nagoya, 464-8681, Japan
-
Fukuoka Sanno Hospital
Fukuoka, 814-0001, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Kagawa University Hospital
Kagawa, 761-0793, Japan
-
Kansia Electric Power Hospital
Osaka, 553-0003, Japan
-
Kyorin University Hospital
Mitaka, 181-8611, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Kyushu University Hospital
Fukuoka, 812-0054, Japan
-
National Cancer Centre Hospital
Tokyo, 104-004, Japan
-
National Cancer Centre Hospital East
Kashiwa-shi, 277-8577, Japan
-
Tohoku University Hospital
Sendai, 890-8574,, Japan
-
Yokohama City University Hospital
Yokohama, 236-0004, Japan